13.03.2012Strategy and Statistics in Clinical TrialsYou are hereEventsLife science events Strategy and Statistics in Clinical Trials
Find an actor
LS2 Annual Meeting 201812.02.2018The biggest Life Sciences conference in Switzerland takes place at the University of Lausanne February 12-13, 2018
Comment la «Health Valley» séduit les start-ups«Ici, il y a une vraie convergence entre les technologies informatiques et le domaine médical, créant un...
Mymetics SATherapeutics & Diagnostics, VaccinesMymetics Corporation (OTCQB: MYMX) is a Swiss-based biotechnology company registered in the US and trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies.
Mymetics develops next-generation preventative vaccines for infectious diseases. Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.
Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus and the RSV vaccine (out licensed to ClearPath – Astellas). The company’s intra nasal Influenza vaccine and the HIV-1 vaccine have successfully completed Phase I clinical trials in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase.